The FDA has approved c11 choline Injection, a Positron Emission Tomography (PET) imaging agent, for use in men to detect prostate cancer recurrences and to locate specific body sites for follow-up tissue sampling, testing and treatment.
The indicated use for c11 choline injection is men with elevated prostate specific antigen (PSA) levels after earlier primary treatment for prostate cancer. c11 choline should not intended as a replacement for tissue testing and sampling prior to additional treatment.
Based on this approval, the Mayo Clinic PET Radiochemistry Facility is the first and only FDA approved c11 choline PET manufacturing facility in the United States. Since c11 choline has an extremely short half life it must be administered immediately after production. Thus, the only place it can be obtained “on label” is at the Mayo Clinic.
c11 choline Injection provides a new imaging contrast to help detect the location of prostate cancer tumors in survivors whose blood tests su